Discover 170 paid clinical trials in Fargo, North Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 170
Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery
for
Corneal Ectasia
Location: W. Fargo ND, Bloomington MN, Bozeman MT, Westerville OH,
Sponsor: Glaukos Corporation
Sex: All
Age: 18+
Code: NCT03319082
Recruiting
Outcomes of a Trifocal IOL in Post-refractive Patients
for
Refractive Errors
Location: W. Fargo ND
Sponsor: Vance Thompson Vision ND
Sex: All
Age: 18+
Code: NCT04545073
Recruiting
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
for
Age-related Wet Macular Degeneration
Location: Fargo ND, Carmel IN, Erie PA, Philadelphia PA,
Sponsor: Caregen Co. Ltd.
Sex: All
Age: 50+
Code: NCT06132035
Phase1, Recruiting
Microbiome and Bariatric Surgery
for
Weight Change, Body
Location: Fargo ND, Cleveland OH
Sponsor: North Dakota State University
Sex: All
Age: 18 - 65
Code: NCT03065426
Recruiting
Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)
for
Atopic Keratoconjunctivitis
Location: Fargo ND, Kansas City MO, Town And Country MO,
Sponsor: Andover Eye Associates
Sex: All
Age: 18+
Code: NCT04296864
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
for
Pruritus
Location: Fargo ND, Bellevue NE, Indianapolis IN, London,
Sponsor: Sanofi
Sex: All
Age: 18 - 70+
Code: NCT05263206
Phase3, Recruiting
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
for
Prurigo Nodularis
Location: Fargo ND, Eagan MN, Saint Joseph MO, Tulsa OK,
Sponsor: Sanofi
Sex: All
Age: 0 - 17
Code: NCT06293053
Phase3, Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
for
Chronic Obstructive Pulmonary Disease
Location: Fargo ND, Rochester MN, Kansas City KS, Evanston IL,
Sponsor: Sanofi
Sex: All
Age: 40 - 70+
Code: NCT07190209
Phase3, Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease